Treatable Traits in Airway Disease: From Theory to Practice

Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision medicine of airway diseases, a strategy based on the identification and treatment of so-called “treatable traits” (TTs) has been proposed. A TT is a recognizable phenotypic or endotypic characteristic that can be assessed and successfully targeted by therapy to improve a clinical outcome in a patient with airway disease. Importantly, TTs can coexist in the same patient, so they are not mutually exclusive. The TT strategy proposes to investigate in each individual patient with chronic airway disease the number and type of TTs present and to treat each of them according to guideline recommendations. This strategy is agnostic (ie, independent) to the traditional diagnostic labels (asthma, chronic obstructive pulmonary disease), so it can be applied to any patient with airway disease. Currently, there is firm evidence supporting the adequacy and validity of the TT strategy. Here, we review the current state of the art of this topic, first by presenting its theoretical background and then by discussing how to best implement it in clinical practice.
Puedes leer el artículo completo aquí: https://www.sciencedirect.com/science/article/abs/pii/S2213219823000764?dgcid=author
Autores: Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald
Noticias relacionadas

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as «Aging (Albany NY)» and «Aging-US» by Web of Science) Volume 15, Issue 14, entitled, «Human senescent fibroblasts trigger progressive lung fibrosis in mice.»

COPD and multimorbidity: recognising and addressing a syndemic occurrence
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer.

Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial.
Más artículos
Estudios
- Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Tobias Welte, Peter J. Barnes and Alvar Agustí. Inhaled corticosteroids for the treatment of COVID-19
- Alvar Agusti, Claus F Vogelmeier, David M G Halpin. Tackling the global burden of lung disease through prevention and early diagnosis (2022/09)
- Vincent Cottin et Al. Syndrome of Combined Pulmonary Fibrosis and Emphysema. An Official ATS/ERS/JRS/ALAT Research Statement.
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en Canva Pro el 02/02/2023 libre de derechos para difusión en blog.